Human transcription factor YY1 represses human immunodeficiency virus type 1 transcription and virion production

David M. Margolis
University of Massachusetts Medical School

Mohan Somasundaran
University of Massachusetts Medical School

Michael R. Green
University of Massachusetts Medical School

Follow this and additional works at: http://escholarship.umassmed.edu/oapubs

Part of the Life Sciences Commons, and the Medicine and Health Sciences Commons

Repository Citation
Margolis, David M.; Somasundaran, Mohan; and Green, Michael R., "Human transcription factor YY1 represses human immunodeficiency virus type 1 transcription and virion production" (1994). Open Access Articles. 1555.
http://escholarship.umassmed.edu/oapubs/1555

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.
Human Transcription Factor YY1 Represses Human Immunodeficiency Virus Type 1 Transcription and Virion Production

DAVID M. MARGOLIS, * MOHAN SOMASUNDARAN, AND MICHAEL R. GREEN

Program in Molecular Medicine, University of Massachusetts Medical Center, Worcester, Massachusetts 01605

Received 9 September 1993/Accepted 27 October 1993

The transcriptional activity of human immunodeficiency virus type 1 (HIV-1) is affected by many cellular factors. Homologs near the HIV-1 initiation region to the DNA-binding sequences of YY1, a multifunctional transcription factor known to regulate diverse viral and cellular promoters, suggested that YY1 might regulate HIV-1. Antibody to YY1 blocked the formation of complexes by HeLa cell nuclear extract and a DNA oligonucleotide encoding the HIV-1 initiation region. HIV-1 long terminal repeat (LTR) expression, as measured by the expression of a transfected LTR-CAT reporter gene, was repressed more than 12-fold by the cotransfection of a YY1 expression vector. HIV-1 production by both COS-1 and CEM cells after transfection of an infectious molecular HIV-1 clone was repressed 7- to 20-fold by cotransfection of a YY1 expression vector. HIV-1 production was also decreased threefold in a CD4-positive lymphocyte cell line chronically infected with HIV-1 (8E5) after transfection of YY1. In situ hybridization studies confirmed that YY1 reduced HIV-1 RNA expression. YY1 may play an important role in the regulation of HIV-1 LTR expression in vivo and virus production by infected cells.

MATERIALS AND METHODS

Plasmids and cell lines. The T-cell lines CEM, 8E5, and ACH2 were maintained in suspension culture in RPMI 1640 medium (ICN Biochemicals, Costa Mesa, Calif.) supplemented with 10% fetal bovine serum (GIBCO, Grand Island, N.Y.). COS-1 and HeLa cells were grown in monolayers in Dulbecco’s modified Eagle’s medium (GIBCO) supplemented with 10% fetal bovine serum. The HIV-1 LTR-chloramphenicol acetyltransferase (CAT) reporter gene construct pILIC (1), the infectious molecular clone of HIV-1 pNL4-3 (1), the Tat expression vector pTat (30), and the β-galactosidase expression plasmid pSV-βgal (19) were prepared by the standard alkaline lysis method. pCMV-YY1 was constructed by insertion of a StyI-EcoRI fragment of the YY1 cDNA plasmid (28) into the BamHI site of the expression vector pCMV-bam/neo3 (15).

Transfections, CAT assays, and p24 ELISA. Monolayer cells were transfected with 20 μg of plasmid DNA by the calcium phosphate procedure (21) with 5 μg of LTR-CAT reporter, 5 or 10 μg of effector DNA, and carrier DNA. Suspension cultures were transfected by the DEAE-dextran method (21) with 1.5 μg of LTR-CAT reporter or 2 μg of pNL4-3 and 1 to 4 μg of effector DNA. CAT assays were performed 48 h after normalization for total protein content (21). To measure transfection efficiency, pSV-βgal was cotransfected and β-galactosidase assays were performed as described previously (19). Aliquots of culture medium were sampled for detection of HIV-1 p24Ag protein. Assays were performed with an antigen capture Coulter enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer’s instructions.

Antibody depletion in EMSAs. Electrophoretic mobility shift assays (EMSAs) with HeLa nuclear extract were performed as described previously with an oligonucleotide corresponding to the −16 to +27 sequence of the HIV-1 LTR (5'-TGCTTTTT GCTTGTACTGGGTCCTCTGGTTAGACGATCTGAG G-3' [21]). The EMSA with YY1 protein was performed as described by Shi et al. (28). For depletion experiments, YY1 antiserum or preimmune serum (gift of T. Shenk) was added to
the EMSA reaction mixture and incubated for a further hour at 4°C; 5 μl of 10% Staphylococcus aureus Cowan cells (Pansorbin; Calbiochem, La Jolla, Calif.) was then added and incubated for an hour at 4°C. The reaction mixture was centrifuged, and the supernatant was run on an acrylamide gel as described before (21).

Detection of HIV-1 RNA by in situ hybridization. Cells were fixed in 4% paraformaldehyde, and in situ hybridization with alkaline phosphatase detection was performed as described before (29).

RESULTS

YY1 antibody interferes with a DNA-protein interaction near the HIV-1 initiator region. Several lines of evidence suggest that YY1 can recognize the HIV-1 LTR initiator region. Bacterially synthesized YY1 protein (gift of Y. Shi) bound an oligonucleotide encoding the LTR -16 to +27 region in EMSAs (data not shown). YY1 is present in HeLa cell nuclear extracts (28). In EMSA competition experiments with HeLa nuclear extract, the labeled LTR -16/+27 probe, and competitor representing the κE3' YY1 binding site (8) of the immunoglobulin kappa light chain 3' enhancer (5'-CCAC CTCCATCTTTG-3'), more than a 30-fold molar excess of κE3' competitor was required to prevent complex formation. In the converse experiment, complexes bound to the labeled κE3' probe were preferentially inhibited by a 10-fold molar excess of the LTR oligonucleotide (data not shown).

The effect of YY1 antiserum on EMSA complexes formed with the LTR oligonucleotide provided further evidence that YY1 is involved in complex formation. In previous EMSA studies, we have found one nonspecific and several specific complexes formed by this oligonucleotide and HeLa nuclear extract (21). YY1 antiserum interfered with the formation of specific complexes by a HeLa nuclear protein and the LTR initiator region, while preimmune serum did not interfere with complex formation (Fig. 1). Nonspecific complexes were unaffected by YY1 antiserum.

YY1 is capable of direct interaction with both DNA and other cellular factors (19). Together, our findings suggest that YY1 or an immunologically related protein complex recognizes the HIV-1 initiator region.

YY1 represses LTR-directed CAT activity. The ability of YY1 to decrease LTR-directed expression of CAT was tested. CEM cells, a CD4-positive lymphocyte line, were cotransfected with the HIV-1 LTR-CAT reporter and pCMV-YY1. In control experiments, the reporter was cotransfected with the unmodified expression vector pCMV-bam/neo3. Compared with the activity of the reporter transfected with the unmodified vector, pCMV-YY1 caused up to 12-fold repression in a dose-dependent manner (Fig. 2). Expression of pSV-βgal, as measured by assays of β-galactosidase activity, varied by less than 10% between selected cultures. Repression was not dependent on promoter sequences upstream of the NF-κB sites, as a reporter (pLTR dl 525/+27) [24]) lacking those sequences was repressed to the same extent as the construct carrying the complete LTR (data not shown). YY1 had a marginal effect on activation mediated by cotransfection with pTat (data not shown).

YY1 decreases HIV-1 production in nonlymphoid cells. To assess the biological relevance of the repression mediated by
YY1 REPRESSES HIV-1 TRANSCRIPTION

FIG. 3. Inhibition of p24<sup>core</sup> production in COS-1 cells. HIV-1 DNA was transfected with pCMV or pCMV-YY1. (A) Concentrations of p24 measured after transfection. For simplicity, data are shown only for 10 µg of pCMV (designated HIV-1); the values for 5 µg of pCMV were nearly identical. Results are representative of three experiments. (B) Fold inhibition was calculated by dividing p24 values measured after cotransfection of HIV-1 DNA and pCMV by values measured after cotransfection of HIV-1 and the indicated amount of pCMV-YY1.

FIG. 4. One day after transfection of COS-1 cells, HIV-1 mRNA was detected by in situ hybridization with alkaline phosphatase (27). Nick-translated, biotinylated whole HIV-1 genomes were used as probes. Cells transfected with HIV-1 and pCMV-YY1 under phase (A) and bright light (B); little dark hybridization signal is seen. Control cells transfected with HIV-1 and unmodified CMV expression vector under phase (C) and bright light (D); copious dark hybridization signal is seen.
YY1, the effect of YY1 on the expression of virus in a model of acute infection was studied. COS-1 cells were cotransfected with pCMV-YY1 or the unmodified vector and with pNL4-3, an infectious and replication-competent molecular clone of HIV-1. COS-1 cells can be efficiently transfected with and support HIV-1 replication and production of infectious virus by this clone (1).

Transfection of pCMV-YY1 resulted in a dose-dependent decrease in the HIV p24 antigen level of nearly 20-fold by 1 day posttransfection. Greater than threefold repression was maintained for up to 10 days in culture (Fig. 3). Cells grew to confluency by day 3; there was no observable difference in growth between cultures. YY1 did not affect the expression of a cotransfected β-galactosidase gene; expression varied by less than 10% between selected cultures tested. In situ hybridization studies of these cells showed decreased expression of HIV-1 mRNA in cultures cotransfected with YY1 (Fig. 4).

**YY1 decreases HIV-1 production in lymphoid cells.** Similar experiments were performed with CD4-positive CEM T cells. Virus production was detected after 3 days in cultured cells cotransfected with pNL4-3 and the unmodified expression vector. In contrast, virus production in cultures cotransfected with pCMV-YY1 was diminished up to sevenfold by 3 to 6 days after transfection (Fig. 5) and then rose to levels comparable to those in other cultures. Throughout the experiments, cell viability, as measured by trypan blue dye exclusion and total cell number, was not decreased by YY1 transfection.

**YY1 decreases virus production in a T cell line chronically infected with HIV-1.** To test the effect of YY1 on HIV-1 expression in cells which constitutively express the virus, 8E5 cells were transfected with YY1. 8E5 cells are CEM-derived cells that contain a single integrated HIV-1 genome and chronically express a low level of virus (9). Cells were transfected with pCMV-YY1 or empty vector (Fig. 6A and B). YY1 repressed HIV-1 production up to threefold 2 days after transfection (Fig. 6C). In situ studies (not shown) again showed decreased HIV-1 mRNA expression in cells cotransfected with YY1.

ACH2 cells are similar to 8E5 cells but produce high titers of HIV-1 upon stimulation by tumor necrosis factor alpha or tetradecanoyl phorbol acetate (TPA) (4). Expression of virus in the basal state, before TPA stimulation, was repressed by transfection of pCMV-YY1. However, YY1 did not block the induction of virus after TPA stimulation (data not shown).

**DISCUSSION**

Integrated HIV-1 DNA is now known to be present in a significant number of CD4-positive lymphocytes during all stages of HIV-1 infection. Viral mRNA, however, is expressed in only a fraction of these cells (6, 7, 25). Many cellular factors have been shown to increase HIV-1 mRNA expression (10-14, 22, 31). Initial reports that the HIV-1 nef gene can downregulate viral expression were refuted by later studies (17, 20). As mRNA expression is restricted despite the abundance of stimulatory factors present in lymphocytes, cellular proteins that downregulate HIV-1 LTR expression must play an important role in the life cycle of HIV-1.

In vitro studies have shown that the cellular factor USF can repress transcription via a binding site in the U3 region (11) and can activate transcription through a site at the initiator (5). LBP-1, first reported to activate transcription (13), has been shown to decrease HIV-1 transcription in in vitro reactions (16). The in vivo role of these factors is unclear.

We have shown that YY1, a cellular transcription factor thought to be widely distributed (28), can downregulate HIV-1 expression. Evidence suggests that YY1 recognizes a site near the initiator region and represses HIV-1 transcription. It should be emphasized that we present no direct evidence that a functional initiator element exists in the HIV-1 LTR (23) or that YY1 directs initiator-mediated transcription of the LTR, as it can in other promoters (27). It is interesting that when acting through bona fide initiator elements, YY1 activates transcription (2, 27). Our findings support the hypothesis that the effect exerted by YY1 is critically dependent on interactions with cellular factors.
Repression was not accounted for by cell death induced by transfection of YY1, as viability measured by trypan blue dye exclusion was unaffected by YY1. β-Galactosidase expression was unaffected by YY1, suggesting that YY1 does not cause nonspecific repression of transcription. In situ hybridization studies demonstrate that repression is mediated at the level of transcription.

For the first time, in tissue culture models of both acute and chronic infection, we have shown that a cellular transcription factor can decrease HIV-1 production. We observed repression in both nonlymphoid (COS-1) and lymphoid (CEM) cells.

Host cell differences may explain the different kinetics of repression observed in these experiments. COS-1 cells are CD4 negative, and so superinfection of cells by progeny virions could not occur. It has been suggested that, after a transient period of virus production, transfected HIV-1 DNA fails to stably integrate into the chromosome of nonlymphoid cells (1). These factors account for the plateau of virus production and sustained effect of YY1 (see Fig. 3) in COS-1 cells. CEM CD4-positive lymphocytes are susceptible to continued rounds of viral replication and reinfection. Consistent with the transient nature of YY1 expression, the peak effect of YY1 was seen 2 to 3 days after transfection of CEM cells. Similarly, maximal repression of virus production in 8E5 cells, a line that chronically produces HIV-1, coincided with the expected peak of YY1 expression.

Repression by YY1 was not irreversible. Repression in ACH2 cells could be ablated by mitogen activation. In the context of transfection of a tat expression vector, YY1 is not capable of significant repression of Tat-activated transcription of an LTR-CAT reporter. However, YY1 can repress HIV-1 expression in models of acute and chronic infection in which the amount of Tat present may be more biologically relevant.

YY1 can form protein-protein contacts with SP1 and perhaps other basic transcription factors (18). Repression by YY1 is likely to be mediated by such interactions. It will be important to determine whether YY1 interacts directly with the LTR or in cooperation with other factors and whether YY1 competes with other factors that can recognize the HIV-1 initiator region.

Our observations suggest that YY1 restricts HIV-1 transcription and production in the unstimulated state but allows
viral expression after appropriate stimulation. The majority of infected cells probably exist in such a state of “transcriptional latency,” capable of virus production upon appropriate activation. It will be important to determine the relative levels of YY1 present in a variety of cell types under a variety of physiological conditions. Understanding of the mechanism of YY1 action and how repression by YY1 is overcome by activating signals may yield important insights into this critical step in the life cycle of HIV-1.

ACKNOWLEDGMENTS

We thank Y. Shi for providing pCMV-YY1, purified YY1, and many helpful discussions. T. Shenk and A. Usheva kindly supplied YY1 antiseraum, and J.-M. Mathias provided assistance with in situ hybridization studies. We are grateful for the advice and guidance of many members of the Green lab. This work was supported by grants from the National Institutes of Health to D.M.M. and M.R.G.

REFERENCES